Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects
- PMID: 2049246
- PMCID: PMC1368323
- DOI: 10.1111/j.1365-2125.1991.tb05551.x
Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects
Abstract
1. The effects of single doses of metoprolol 50 mg, metoprolol 100 mg and atenolol 100 mg on exercise tolerance were compared with placebo in a double-blind random cross-over study in 12 healthy subjects. Nine subjects were extensive metabolisers of debrisoquine, and three were poor metabolisers. 2. Three hours after dosing beta-adrenoceptor blocker treatments significantly reduced exercise heart rate, prolonged time to complete exercise, and increased subjective fatigue measured by visual analogue scale. 3. Scores for subjective fatigue did not correlate with reduction in exercise heart rate or prolongation of exercise time. Exercise time prolongation was weakly but not significantly correlated with exercise heart rate reduction. 4. When compared with placebo, prolongation of exercise time and increased fatigue with metoprolol were not significantly related to debrisoquine oxidation phenotype or to the debrisoquine/4-hydroxydebrisoquine (D/4OH-D) ratio. 5. When metoprolol responses were compared with those for atenolol, changes in exercise time and fatigue scores were significantly related to oxidation phenotype. For metoprolol 100 mg, poor metabolisers required 20.8 s longer to complete exercise (P less than 0.05) and had higher fatigue scores by 78% (P less than 0.05) as compared with extensive metabolisers.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.Br J Clin Pharmacol. 1985 Mar;19(3):329-33. doi: 10.1111/j.1365-2125.1985.tb02651.x. Br J Clin Pharmacol. 1985. PMID: 2859048 Free PMC article.
-
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.Br J Clin Pharmacol. 1985 Dec;20(6):555-66. doi: 10.1111/j.1365-2125.1985.tb05112.x. Br J Clin Pharmacol. 1985. PMID: 2868742 Free PMC article.
-
Duration of beta-blockade with metoprolol and atenolol: influence of drug oxidation.Postgrad Med J. 1983;59 Suppl 3:36-7. Postgrad Med J. 1983. PMID: 6647208 Clinical Trial.
-
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001. Clin Pharmacokinet. 1986. PMID: 2868819 Review.
-
Oxidation phenotype and the metabolism and action of beta-blockers.Klin Wochenschr. 1985 Apr 1;63(7):285-92. doi: 10.1007/BF01731972. Klin Wochenschr. 1985. PMID: 2860267 Review.
Cited by
-
Genetically determined adverse drug reactions involving metabolism.Drug Saf. 1993 Jul;9(1):60-77. doi: 10.2165/00002018-199309010-00006. Drug Saf. 1993. PMID: 8347292 Review.
-
CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.Pharm Res. 2017 Aug;34(8):1615-1625. doi: 10.1007/s11095-017-2104-8. Epub 2017 Feb 8. Pharm Res. 2017. PMID: 28181117 Free PMC article.
-
Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.Drugs. 1992 Mar;43(3):382-414. doi: 10.2165/00003495-199243030-00006. Drugs. 1992. PMID: 1374320 Review.
-
Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.Br J Clin Pharmacol. 1993 Dec;36(6):531-8. doi: 10.1111/j.1365-2125.1993.tb00411.x. Br J Clin Pharmacol. 1993. PMID: 12959269 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical